XOMA Co. (NASDAQ:XOMA) Shares Sold by Fmr LLC

FMR LLC reduced its stake in shares of XOMA Co. (NASDAQ:XOMA - Free Report) by 4.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,102,401 shares of the biotechnology company's stock after selling 51,003 shares during the quarter. FMR LLC owned 9.36% of XOMA worth $29,192,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in XOMA. Ellsworth Advisors LLC acquired a new stake in shares of XOMA in the third quarter valued at approximately $516,000. Rhumbline Advisers boosted its position in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock worth $230,000 after acquiring an additional 1,334 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in XOMA during the first quarter worth approximately $212,000. Finally, Bank of New York Mellon Corp boosted its position in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock worth $1,484,000 after acquiring an additional 1,968 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on XOMA shares. StockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a research report on Wednesday, August 14th. HC Wainwright reissued a "buy" rating and issued a $123.00 target price (up previously from $117.00) on shares of XOMA in a research note on Monday, December 2nd.

Insider Activity

In related news, CEO Owen Hughes sold 21,881 shares of the firm's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares of the company's stock, valued at approximately $1,047,621.05. This trade represents a 38.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.20% of the company's stock.

XOMA Trading Down 2.7 %

Shares of XOMA stock traded down $0.82 during mid-day trading on Tuesday, reaching $29.49. The company's stock had a trading volume of 41,552 shares, compared to its average volume of 22,521. The company's 50 day simple moving average is $29.94 and its 200-day simple moving average is $27.61. XOMA Co. has a 12-month low of $14.77 and a 12-month high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $347.48 million, a PE ratio of -8.47 and a beta of 0.88.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.